| Name | Title | Contact Details |
|---|
ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types.
Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D.
Clinical trials are designed around endpoints, but its the beginning that sets them up for success—including selecting the best RTSM partner for continuous and flexible support throughout the duration of a trial. With decades of experience, Endpoint Clinical is obsessed with proactive problem-solving, ensuring that issues are anticipated and resolved before they escalate, and any changes are easily incorporated. From day one, we become an extension of your team, seamlessly integrating into your trial operations. We minimize friction, reduce risk, and enable your clinical teams to focus where it matters most—on trial success. Endpoint is headquartered in Raleigh, NC, with offices across the US, EU, and Asia.
Actuate Therapeutics, Inc. is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration.
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.